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Abstract
Very little is known about the etiology of ovarian
cancer. However, studies have shown that occupational
exposure to polycyclic aromatic hydrocarbons (PAHs)
and tobacco smoking can increase ovarian cancer risk.
Previously, we have determined that 100% of ovarian
tumors show loss or aberrant subcellular localization of
TACC3 (transforming acidic coiled coil 3) relative to
the normal ovarian surface epithelium (OSE). In mice,
a role for TACC3 in the cellular response to PAH has
been defined. However, comparable studies for human
TACC3 has not been performed. In this report, we
show that specific knockdown of TACC3 in human
ovarian cancer cells increases the basal level, and
distorts the PAH-induced expression, of genes
involved in metabolizing the procarcinogen PAH
benzo[a]pyrene to its DNA damaging epoxide. In
addition, we demonstrate that PAH stabilizes the
TACC3 protein and induces the export of TACC3 and
one of its binding partners, Ku70, from the nucleus.
This parallels the subcellular distribution of TACC3 in
those ovarian cancers that express TACC3. These data
suggest that functional downregulation of TACC3
could aid tumor progression by altering cellular
responses to chemical carcinogens and the DNA
damage that they induce.
Introduction
Ovarian cancer accounts for 4-6% of all cancers in
women, but has an overall survival rate of less than
40%, a higher mortality than any other gynecological
malignancy (Greenlee et al 2000). In part, this low
survival rate is due to our poor understanding of the
mechanisms underlying initiation and progression of
this cancer and thus efficient prevention and adequate
early detection. While BRCA1 and BRCA2 mutations
account for 35-50% of familial ovarian cancer
(Gayther et al 1999, Werness et al 2000), the
etiological basis of sporadic ovarian cancer is still
unclear, with no single high penetrance gene defect
significantly associated with the initiation of the
sporadic cancer. Instead, it is likely that, as with most
human cancer, ovarian cancer is due to the poorly
understood interactions between environmental insults
and low penetrance genetic factors.
Occupational exposure to complex organic
compounds, such as PAHs, is associated with up to 4-
fold elevated risk of ovarian cancer (Shields et al 2002,
Langseth et al 2004, Guo et al 2004). However, PAHs
are also common environmental pollutants, chiefly as
products of incomplete combustion, being found in
charred food, fossil fuel exhaust and cigarette smoke.
Benzo[a]pyrene (B[a]P) is one of the most prevalent
PAH in tobacco smoke, and studies have linked
cigarette smoking with an increased risk of developing
several cancers, including forms of ovarian cancer
(Green et al 2001, Terry et al 2003, Pan et al 2004,
Zhang et al 2004, Niwa et al 2005, Jordan et al 2006,
Rossing et al 2008).
The normal mechanism for clearance of PAHs
requires the metabolism of the hydrophobic compound
to a less toxic and more water soluble metabolite that
can be excreted from the body (Jakoby et al 1982).
Phase I metabolic enzymes are responsible for the
initial hydroxylation or metabolic reduction of the
hydrocarbon. The genes encoding these enzymes, such
as CYP1A1 and CYP1B1, are induced by the liganded
arylhydrocarbon receptor (AhR), heterodimerized to
the AhR-nuclear translocator (ARNT) protein (Zhang
et al 1998, Tsuchiya et al 2003). However, for some
species of PAH, Phase I metabolism results in the
activation of the initial PAH to a more potent and
chemically active compound. For instance, the
prototypical PAH, B[a]P, can be activated, first to the
7,8-epoxide intermediate, and then to the
corresponding diol-9,10-epoxide (BPDE) (Harvey
1991). Failure to clear these reactive epoxides can then
result in the formation of DNA adducts, which are
normally identified and removed by DNA damage
response and repair pathways. The major pathway
responsible for the repair of PAH-damaged DNA is
nucleotide excision repair (NER) (Yang et al 1982,
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MacLeod et al 1991), with double-strand DNA break
(DSB) repair and mismatch repair (MMR) playing
auxiliary roles (Toyooka et al 2004, Wu et al 2003).
However, such repair can be further compromised, as
the epoxides themselves are potent inhibitors of
estrogen regulated BRCA1 expression (Jeffy et al
1999, 2002). Thus, the accumulation and incorrect
repair of PAH-DNA adducts can lead to mutations and
genetic damage involving homologous and non-
homologous recombination (Abe & Sasaki 1982,
Sasaki 1982), thereby increasing ovarian cancer risk.
Several cancers, in particular, breast, ovarian,
endometrial and cervical cancers exhibit loss of
chromosome 4p16 (Forozan et al 2000, Ramus et al
2003, Sherwood et al 2000, Suzuki et al 2000, Wang et
al 2004), the site of the TACC3 gene (see Eslinger et al
2009 for review). We have found 1) that 100% of
ovarian tumors show loss or aberrant subcellular
localization of TACC3, 2) constitutional mutations in
the TACC3 gene in patients with ovarian cancer, in the
absence of mutations in known predisposition genes
and 3) several novel coding substitutions in sporadic
ovarian tumors that could interfere with
posttranslational modifications and interactions that
govern TACC3 function (see Eslinger et al 2009 and
references therein). Combined, these data suggest that
the functional inactivation and/or dysregulation of
TACC3 plays a pivotal role in malignant progression
in a significant number of ovarian tumors.
In the mouse, TACC3 is involved in the cellular
response to PAH through a direct interaction with the
ARNT1 protein (Sadek et al 2000). However, similar
analyses of the human TACC3 protein have not been
carried out. In this manuscript, we examine the
potential role of TACC3 in responses to PAH in human
ovarian cancer. We show that specific knockdown of
human TACC3 in ovarian cancer cells increases the
basal transcriptional level of genes involved in
metabolizing B[a]P, however TACC3 knockdown also
reduces the usual induction of the Phase I enzyme
CYP1A1. PAH also induces a partial redistribution of
TACC3 from the nucleus to the cytoplasm. These data
suggest that the functional downregulation of TACC3
observed in most ovarian tumors aids tumor
progression by altering cellular responses to chemical
carcinogens and the DNA damage that they induce.
Materials and Methods
Cell lines and immunological procedures
A2780, SkOV3 and HeLa cells were obtained from
ATCC and maintained in DMEM +10% fetal calf
serum containing the antimycotic/antibiotic normocin
(Invivogen, USA). α-TACC 3 antibody was described 
in Gangisetty et al (2004). Secondary antibodies and
conjugates were obtained from Jackson Laboratories.
For protein extraction, cells were washed with ice-
cold 1xPBS. Nuclear and cytoplasmic extracts were
prepared according to the protocol of Schreiber et al
(1989), while whole cell lysates were prepared as
previously described in Lauffart et al (2007b). Proteins
were separated by 8% w/v SDS-PAGE and
immunoblotted with respective antibodies as described
in Lauffart et al (2007b).
siRNA-mediated downregulation of TACC3 and semi
quantitative rt-PCR analysis
The 21 nucleotide siRNA used to target human
TACC3 was previously described and used in Lauffart
et al (2007a). siRNA controls were obtained from
Dharmacon, USA. All siRNAs were manipulated
according to manufacturer’s instructions. Briefly, cells
were plated in triplicate into 24 well plates. After
attachment, the cells were treated with 100nM siRNA
to TACC3 or 100nM control siRNA (Dharmacon,
USA) in the presence of 5nM siGLO (transfection
efficiency control) for 48hrs prior to further treatment
with PAH, and/or harvest. cDNA was prepared from
1μg of RNA using the iScript cDNA synthesis system 
(BioRAD, USA), according to manufacturer’s
instructions. Expression of a selection of the PAH
response battery, cytochrome P450s CYP1A1 and
CYP1B1, NADPH dehydrogenase, quinone 1 (NQO1)
and aldehyde dehydrogenase 3c (ALDH3c) was
analyzed by semiquantitative reverse transcription-
polymerase chain reaction (rt-PCR). Actin was used as
a quantification control. Amplification primers were
selected from adjacent exons in each gene to readily
detect any genomic contamination (sequences and
amplification conditions are available upon request).
PCR amplification was performed for 25 cycles and
repeated three times. All results shown were obtained
from the same experiment, but similar results were
obtained in the replicates.
Results and Discussion
The ARNT1 binding region located in the TACC
domain of TACC3 is conserved between species
(Eslinger et al 2009). Thus, due to this degree of
conservation, we predicted that human TACC3 has a
functional role in the transcriptional regulation of PAH
responsive genes such as CYP1A1 and CYP1B1. We
tested this hypothesis by examining the effect of
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siRNA-mediated inhibition of endogenous TACC3 in
two ovarian cell lines A2780 and SkOV3, and the
cervical cancer cell line HeLa. As shown in Fig. 1A,
transient transfection of a TACC3 siRNA, increased
the constitutive expression level of CYP1B1 in A2780
and SkOV3. Induction of two other genes in the PAH
“response battery”, NQO1 and ALDH3c was also
noted, in the absence of PAH. Intriguingly, this effect
was specific to the ovarian cancer cell lines, and was
not observed in the cervical cancer cell line, HeLa. In
SkOV3, a complete knockdown of endogenous human
TACC3 expression resulted in induction of CYP1A1 in
the absence of B[a]P, which then only increased an
Figure 1: siRNA-mediated downregulation of TACC3 increases the
base level of PAH response and metabolizing genes (A), but
reduces transcriptional induction upon PAH exposure (B). (A):
A2780 (A), SkOV3 (S) or HeLa (H) cells were treated with siRNA
to TACC3 (T3) or control siRNA (C) (Dharmacon, USA) for 48hrs
prior to harvest (see Materials and Methods). Semiquantitative rt-
PCR was performed as detailed in Materials and Methods. Basal
levels of Cyp1B1, Nqo1 and Aldh3c increased in the ovarian
cancer cell lines, but not the cervical cancer cell line HeLa. (B):
Effect of TACC3 knockdown on PAH-induced expression of
CYP1A1 in SkOV3. Experimental procedures were as described in
(A), however, prior to harvest, the transfected cells were treated
with 5μM B[a]P for the indicated times. 
additional two fold after exposure to the PAH for 24
hours (Fig. 1B). Intriguingly, these findings
recapitulate the observation that many ovarian tumors
express high levels of CYP1A1 and CYP1B1, even in
the absence of PAH stimulation (Leung et al 2005,
McFadyen et al 2001). These results suggest that
TACC3 can act as both a transcriptional repressor in
the absence of PAH and an activator when PAH is
present. This type of effect is known for several
transcriptional regulators. Thus, TACC3 may play a
similar function to the FHL and FOG families [with
which it also interacts (Garriga-Canut and Orkin 2004,
Lauffart et al 2007b)] acting as either a corepressor or
coactivator, depending upon the context of the
promoter and the availability of ligand [similar to
PGC-1 (Tcherepanova et al 2000, Delerive et al
2002)]. Alternatively, TACC3 may act as a promoter-
specific transcriptional switch, changing from a
transcriptional repressor to an activator, as noted for
TIF1, and CBF-1/RBP-J in the Notch signaling
pathway (Kao et al 1998). Previously characterized
TACC3 interactions suggest that either mechanism is
possible as TACC3 directly binds to methyl-binding
protein (MBD) at methylated promoters (Angrisano et
al 2006) and histone acetyltransferases (Gangisetty et
al 2004). Thus, TACC3 may normally stabilize histone
deacetylases bound to methylated promoters, such as
that of uninduced CYP1A1 (Schnekenburger et al
2007), but then bring in histone acetyltransferases,
triggering activation of the previously methylated
promoter when the cell is exposed to PAH.
Consequently, the observed loss of TACC3 from the
nucleus in ovarian tumors (Lauffart et al 2005) could
be associated with abnormalities in PAH metabolism in
the OSE and its malignant derivatives.
Dynamic posttranslational modifications by
ubiquitin regulate the structural integrity and stability
of several proteins involved in the response to PAH
and the genetic damage that they induce (Ma &
Baldwin 2000, Glockzin et al 2003, Ng et al 2003).
Furthermore, based upon current interactome data,
TACC proteins are predicted to interact with ubiquitin
conjugating enzymes (Lauffart et al 2007a). To
determine whether PAH induces changes in TACC3
stability via the ubiquitin-proteasome pathway, parallel
cultures of the ovarian cancer cell lines A2780 and
SkOV3 were treated with B[a]P in the presence of the
26S proteasome inhibitor MG132. In addition, the cells
were treated with a combination of MG132 and BP. As
shown in Fig. 2, B[a]P and MG132 individually
increase the steady state level of the TACC3 protein.
The combination of the two reagents produced a
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Figure 2: Treatment of ovarian cancer cells with benzo[a]pyrene
stabilizes endogenous TACC3. Cells were treated for 6hr with
DMSO (V), 20µM MG132 (MG), 5µM benzo[a]pyrene (BP) or a
combination of MG132 and benzo[a]pyrene (MG+BP). 10g of
whole cell extract was immunoblotted, and incubated with -
TACC3 antisera. -Tubulin was used to demonstrate equivalent
loading of samples.
synergistic effect, which is more pronounced in A2780,
than SkOV3. Recently, two sites in TACC3, K562 and
K673, have been identified as ubiquitinylation targets
in human embryonic kidney, HEK293T, cells and
MV4–11 acute monocytic leukemia cells grown under
standard conditions, although neither site was regulated
by MG-132 (Wagner et al 2011). However, the data
from the two ovarian cancer cell lines presented here
suggests that in response to PAH exposure, TACC3
may be protected from proteolytic degradation by the
26S proteasome, potentially enhancing TACC3’s
capability to induce PAH response genes.
In order for TACC3 to affect transcription of PAH
response genes, logically TACC3 must be located in
the nucleus. Indeed, TACC3 is located in the nuclei of
normal ovarian surface epithelial cells (Lauffart et al
2005). To further confirm that this was also the case in
the ovarian cancer cell lines that were used in this
study, we isolated nuclear and cytoplasmic extracts
from A2780 and SkOV3 exposed to B[a]P over a
period of 8 hours. Surprisingly, after 2 hours, a small
and increasing amount of TACC3 begins to leave the
nucleus of A2780 (Fig. 3). Intriguingly Ku70 also exits
the nucleus. TACC3 is known to bind to and colocalize
with Ku70 in the nucleus of A2780 (Lauffart et al
Figure 3: Benzo-[a]-pyrene causes TACC3 and Ku70 to exit the
nucleus. A2780 ovarian cancer cells were treated with B[a]P for 0-
8 hours. Nuclear and cytoplasmic extracts were isolated from
treated cells and electrophoresed as described in Materials and
Methods. pCAF and -tubulin were used as loading control and to
test for successful separation of nuclear vs. cytoplasmic fractions.
2007b). The PAH-induced effect appears specific as
neither the arylhydrocarbon receptor, nor the histone
acetyltransferase pCAF [also a TACC3 interacting
protein (see Eslinger et al 2009 for review)] exits the
nucleus. Ku70 is known to have a number of functions,
of relevance to oncogenic transformation including
transcriptional activation or repression of a subset of
genes (Gullo et al 2006). Thus, export of Ku70 may
also contribute to expression of the PAH-battery by
removal of another potential transcriptional repressor
from the nucleus. However, a relatively new role for
Ku70 in the control of Bax-mediated apoptosis in the
cytoplasm has been identified (Cohen et al 2004). We
have previously observed that siRNA-mediated
repression of TACC3 significantly increased the
sensitivity of A2780 to a DNA damaging agent
adriamycin, in an apparently p53-dependent manner
(Lauffart et al 2007a). Furthermore, a physical
interaction between normal TACC3 and normal p53
may be an important mediator for establishing cell
cycle arrest, repair of DNA damage and/or apoptosis
(Lauffart et al 2007a). Thus, it is intriguing to speculate
that the export of TACC3 and Ku70 from the nucleus
is also involved in the regulation of similar cell cycle
arrest and apoptotic events triggered by PAH exposure.
Conclusions and Perspectives
Previously published material and the data
presented in this manuscript suggest that human
TACC3 acts at several key points in the response to
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PAH and the DNA damage they cause (Fig. 4). This
suggests that functional loss of TACC3 from the
nucleus, noted in 100% of tumors analyzed to date,
could increase aberrations in cell cycle control and
DNA damage repair/responses when cells are exposed
to PAH, contributing to the accumulation of mutations
that results in the dedifferentiation and malignant
development of the ovarian surface epithelium.
Figure 4: A functional model for TACC3’s involvement in PAH-
induced events in the OSE. TACC3 normally inhibits the basal
expression of Phase 1 metabolizing enzymes by recruitment of
histone deacetylases to the promoters of the respective genes (blue
inhibitory pathway). Upon insult by PAH (blue arrow), TACC3
could participate in the attempt to remove PAHs from the system
by recruiting AhR/ARNT to the promoters of genes encoding PAH
metabolizing protein, and switching out HDACs for histone
acetyltransferases, such as pCAF and CBP/p300 (blue arrow). This
would increase the expression of the Phase 1 enzymes such as
CYP1A1 (green arrow), converting PAH to the damaging epoxide.
Accumulation of PAH-DNA adducts normally triggers cell cycle
arrest and either correct DNA repair or apoptosis (grey arrow)
Direct physical/functional interactions of TACC3 with cell cycle
regulator p53, DNA damage response and repair complexes
(containing BARD1/BRCA1, HHR23 Ku70 and pCAF) and
apoptotic regulators (p53 and Ku70) could then promote restoration
of normal cellular function by removing DNA adducts and
mutations that they may induce, or death of the damaged cell.
Functional loss of TACC3, early in the tumorigenic cycle, could
increase the basal level of CYP1A1 in the OSE, increasing the
turnover of PAH to the DNA-damaging epoxide and subsequent
accumulation of PAH-DNA adducts. Absence of TACC3 from
complexes involved in cell cycle arrest and DNA damage
response/repair could also aid in accumulation of mutations either
as an early or late event contributing to an increased risk of
tumorigenesis and progression, (red arrows). Proteins involved in
these pathways, which are known to interact directly or indirectly
with TACC3, are indicated in parentheses.
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